Status:
COMPLETED
Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer
Lead Sponsor:
Sanofi
Conditions:
Osteoporosis
Prostate Cancer
Eligibility:
MALE
60+ years
Brief Summary
Patients with prostate cancer treated in outpatient clinics will be recruited by their urologist physician. Primary Objective: To evaluate the compliance in male patients with prostate cancer treated...
Eligibility Criteria
Inclusion
- Man with Prostate Cancer
- Men ≥70 years old or ≥60 years old treated by LH-RH agonist for at least 2 years or Man who was diagnosed in the past with Osteopenia/osteoporosis
- Osteopenia/osteoporosis proven by bone density test.
Exclusion
- Creatinine clearance \< 30ml/min
- Hypercalcemia
- Actual treatment by Bisphosphonate or steroids
- Hypersensibility to Bisphosphonate or any contraindication to its use.
- Metastatic prostate Cancer
- Patients not suitable for compliance.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00816452
Start Date
January 1 2009
End Date
July 1 2010
Last Update
November 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-aventis administrative office
Netanya, Israel